Home / Stock ratings / Healthcare Stocks / CVS

Stock rating · Retail-Drug Stores and Proprietary Stores

CVS Health Corporation (CVS) Stock Rating & Analysis

As of November 20, 2026, MELANY rates CVS Health Corporation 67 out of 100 (Favorable). Its highest factor score is earnings track record at 100, and its lowest is catalyst setup at 36.

MELANY ratingRated 2026-11-20

CVS · composite score

67/100
Favorable
Nov 20
Rating date
Live price in the app →
Quality44
Momentum42
Risk-adjusted75
Source basis SEC filings and live market dataDated snapshot

About CVS Health Corporation

CVS Health provides a range of healthcare services. Rooted in retail pharmacy, it runs roughly 9,000 stores, mostly in the US. Through Caremark it is a large pharmacy benefit manager processing about 2 billion adjusted claims a year, and through Aetna it operates a major health insurer serving about 27 million medical members. Its Oak Street Health acquisition added primary care.

Rating as of 2026-11-20 · this is a dated snapshot; the live rating and the live price are in the app (the rating is part of Pro, free for 30 days).

Why CVS scores 67/100

CVS's 8 factor scores run from 36 to 100, and 4 of them sit above its composite of 67. Here is how CVS breaks down.

Valuation86/100

Whether the price looks cheap or expensive against earnings, growth, and peers.

  • P/E 9.4x vs sector 22.0x median
  • PEG ratio 0.19 (< 1 = undervalued)
  • FCF yield 15.1%
Business quality44/100

Margins, returns on capital, and balance-sheet strength.

Price momentum42/100

Direction and relative strength of the recent share-price trend.

Earnings track record100/100

History of beating or missing estimates, and where estimates are heading.

  • Beat EPS estimates 4 of last 4 quarters
  • Avg EPS beat +22%
Analyst sentiment81/100

What Wall Street price targets and revisions are signalling.

  • Analyst targets 35% upside
Catalyst setup36/100

Near-term events that could move the stock.

Risk-adjusted profile75/100

Upside weighed against volatility and drawdown risk.

Macro fit50/100

How the current rate and market regime suits this kind of company.

How CVS compares

As of November 20, 2026, CVS Health Corporation is tied for 4th of 20 in Healthcare Stocks, where the average score is 62.

All stock rating pages.

Key risks for CVS

  • Performance partly driven by Healthcare sector, rotation away from this theme would hurt

Sector and theme context

CVS Health Corporation sits in the Healthcare sector theme, which MELANY currently rates 99/100 for strength. Theme strength feeds CVS's momentum and catalyst factors above.

CVS trade plan (Pro)

MELANY has a full position plan for CVS Health Corporation: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.

Suggested entry zoneLocked
Alert levelLocked
Position sizingLocked
Review triggersLocked

How MELANY rates CVS

MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. CVS Health Corporation's 67/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.

Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.

Frequently asked questions about CVS

Is CVS Health Corporation (CVS) a buy?

As of 2026-11-20, MELANY rated CVS Health Corporation Favorable with a composite score of 67/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.

How does CVS rank against similar companies?

As of November 20, 2026, CVS Health Corporation is tied for 4th of 20 in MELANY's Healthcare Stocks list, where the average score is 62. Among the other names in the list, the highest scores belong to REGN (74) and MDT (71).

Should I buy CVS Health Corporation stock?

That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates CVS Health Corporation (CVS) Favorable with a composite of 67/100 as of 2026-11-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.

What is the CVS stock price forecast?

MELANY does not publish price targets or forecasts for CVS. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 67/100 across eight factors for CVS Health Corporation, and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for CVS as of 2026-11-20: its analyst sentiment factor is 81/100 (Analyst targets 35% upside), and its price momentum factor is 42/100.

Is CVS stock overvalued or undervalued?

MELANY's valuation factor currently reads 86/100 for CVS Health Corporation, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives CVS's read.

What price should I buy CVS at?

Rather than chasing the current price, MELANY computes a smart entry zone for CVS: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.

What are the risks of buying CVS stock?

The top risks MELANY currently flags for CVS Health Corporation: Performance partly driven by Healthcare sector, rotation away from this theme would hurt. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.

Is CVS Health Corporation a good long-term investment?

For long-term durability the two factors that matter most are business quality, which MELANY scores 44/100 for CVS Health Corporation, and earnings track record, at 100/100. The 67/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.

Will CVS stock go up?

Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 42/100 for CVS right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.

How current is this CVS rating?

The rating on this page is a snapshot of MELANY's read as of 2026-11-20, and the score is not recomputed on this page. MELANY re-scores CVS as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).

How this rating works

Market Eyes Live

Every rating graded in public, CVS included

MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.

Get the free iOS app Create a free account on the web Free account, no card. Pro: 30 days free, then $9.99 a month.